Poly Medicure posts Q1 FY25 consolidated PAT at Rs. 74.03 Cr
Poly Medicure has reported total income of Rs. 401.69 crores during the period ended June 30, 2024
Poly Medicure has reported total income of Rs. 401.69 crores during the period ended June 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 364.05 crores during the period ended June 30, 2024
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
RPG Life Sciences has reported total income of Rs. 167.79 crores during the period ended June 30, 2024
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
This transaction is the third acquisition by three different Japanese players in this segment
Cyclosporine Ophthalmic Nanoemulsion is a preservative-free Nanoemulsion that has been approved in South Korea, Peru and several countries in the Middle East for treatment of dry eye syndrome
The pooled prevalence of GERD in the Indian population is 15.6 %
Vimta Labs has reported total income of Rs. 82.44 crores during the period ended June 30, 2024
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
The company is planning to expand its plant capacity in in Vapi
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Subscribe To Our Newsletter & Stay Updated